In EGPA, Fasenra outperforms Nucala at reducing steroid use
Fasenra (benralizumab), which is approved for a rare type of asthma, and Nucala (mepolizumab) were similarly effective at inducing remission in eosinophilic granulomatosis with polyangiitis (EGPA), but more people on Fasenra were able to stop using oral corticosteroids (OCS), with fewer monthly injections. That’s according to final published…